Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akebia Initiates Patient Dosing In AKB-6548 Phase 1b Trial
The Phase 1a study of AKB-6548 has demonstrated a dose-related increase in erythropoietin with no significant adverse events. Akebia said that the Phase 1b study is designed to
The Phase 1a study of AKB-6548 has demonstrated a dose-related increase in erythropoietin with no significant adverse events. Akebia said that the Phase 1b study is designed to
The 15-year clinical study demonstrated that more than 80% of patients were still walking without assistance despite a mean MS disease duration of 22 years, and two-thirds of
According to the warning letter, Eli Lilly was unsuccessful in carrying out sufficient investigation of critical deviations and the failure of a batch to satisfy its quality standards
As per the terms of the settlement, Ethex will plead guilty to criminal charges, and will be required to pay a fine and restitution of $25.8m. Ethex also
The lawsuit claimed that the company advocated biliary stents in the treatment of obstructions in peripheral blood vessels. The companies that make them are barred from promoting or
Sandoz claimed that Menges is one of the three main biopharmaceutical development and production centers within Sandoz worldwide, and a center for cell culture and modified protein technology.
The article, entitled ‘Hereditary Breast and Ovarian Cancer Testing Integration and Outcomes within Community Oncology Practices,’ was published in the February 2010 issue of the journal Community Oncology.
The agreement comes on top of the recent grant of reimbursement in China on two of Lundbeck’s key products Cipralex and Ebixa. As part of the agreement Lundbeck
According to the interim analysis the safety profile was similar between the treatment and placebo arms. Based on a composite efficacy endpoint assessing time to treatment failure (including
Under the agreement Transgenomic will develop the test in its CAP-accredited and CLIA-certified laboratory and anticipates to launch the new test in the second quarter of 2010. Craig